Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  midostaurin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-13 of 13 for your search:
Start Over
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 59
Sponsor: NCI, Other
Protocol IDs: CALGB-10603, EUDRACT-2006-006852-37, CDR0000590404, NCT00651261
Phase I/II Study of PKC412 With or Without Itraconazole in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-02021, NOVARTIS-CPKC412A2104, NCI-G02-2107, UCLA-0305058-01, NCT00045578
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 3 months to 18 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412A2114, 2008-006931-11, NCT00866281
PKC412 and 5-Azacytidine
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0374, NCI-2012-01896, NCT01202877
Phase II PKC412 in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMMPD0003, 95242, Novartis 2213, 13704, NCT00233454
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, 2008-000280-42, NCT00782067
Midostaurin in Indolent Systemic Mastocytosis
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCG41973, NCT01920204
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-CPKC412A2106, UCLA-0308139-01, CDR0000389242, NCT00093600
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-269, NCT00819546
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12010, CPCK412AUS06T, NCT01130662
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-1181 / 201108160, NCT01161550
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-09111, NCI-2010-01335, NCT01174888
Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase: No phase specified
Type: Behavioral study, Natural history/Epidemiology, Treatment
Status: Completed
Age: 60 and older
Sponsor: Other
Protocol IDs: 2004-0060, NCT00459524
Start Over